X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (303) 303
Patent (133) 133
Publication (12) 12
Conference Proceeding (5) 5
Book Chapter (2) 2
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
electricity (122) 122
humans (102) 102
index medicus (100) 100
male (89) 89
basic electric elements (88) 88
electric solid state devices not otherwise provided for (88) 88
semiconductor devices (88) 88
female (87) 87
general tagging of cross-sectional technologies spanning over several sections of the ipc (87) 87
general tagging of new technological developments (87) 87
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (87) 87
technologies or applications for mitigation or adaptation againstclimate change (87) 87
reduction of greenhouse gas [ghg] emissions, related to energygeneration, transmission or distribution (86) 86
aged (75) 75
middle aged (75) 75
oncology (68) 68
adult (61) 61
cancer (53) 53
chemotherapy (53) 53
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
medicine & public health (34) 34
electric communication technique (33) 33
metastasis (33) 33
colorectal cancer (32) 32
stomach cancer (31) 31
treatment outcome (31) 31
analysis (30) 30
physics (29) 29
cancer research (28) 28
care and treatment (28) 28
gastric cancer (28) 28
research (28) 28
aged, 80 and over (27) 27
colorectal neoplasms - drug therapy (26) 26
stomach neoplasms - drug therapy (25) 25
gastroenterology & hepatology (24) 24
amusements (23) 23
card, board, or roulette games (23) 23
games (23) 23
games not otherwise provided for (23) 23
human necessities (23) 23
indoor games using small moving playing bodies (23) 23
sports (23) 23
stomach neoplasms - pathology (23) 23
surgical oncology (23) 23
video games (23) 23
wireless communications networks (23) 23
disease-free survival (22) 22
survival (22) 22
fluorouracil (21) 21
oxaliplatin (21) 21
retrospective studies (20) 20
survival rate (20) 20
antimitotic agents (19) 19
antineoplastic agents (19) 19
camptothecin - analogs & derivatives (19) 19
cisplatin (19) 19
drug combinations (19) 19
neoplasm staging (19) 19
prognosis (19) 19
animals (18) 18
gastroenterology (18) 18
oncology, experimental (18) 18
trial (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
calculating (17) 17
clinical trials (17) 17
computing (17) 17
counting (17) 17
electric digital data processing (17) 17
layered products (17) 17
layered products, i.e. products built-up of strata of flat ornon-flat, e.g. cellular or honeycomb, form (17) 17
performing operations (17) 17
telephonic communication (17) 17
transporting (17) 17
abdominal surgery (16) 16
fluorouracil - administration & dosage (16) 16
leucovorin - administration & dosage (16) 16
patients (16) 16
tegafur - administration & dosage (16) 16
bevacizumab (15) 15
cancer patients (15) 15
irinotecan (15) 15
japan (15) 15
adenocarcinoma - drug therapy (14) 14
colorectal neoplasms - pathology (14) 14
organoplatinum compounds - administration & dosage (14) 14
oxonic acid - administration & dosage (14) 14
camptothecin - administration & dosage (13) 13
cisplatin - administration & dosage (13) 13
colorectal neoplasms - mortality (13) 13
kaplan-meier estimate (13) 13
leucovorin (13) 13
leucovorin - adverse effects (13) 13
1st-line therapy (12) 12
1st-line treatment (12) 12
capecitabine (12) 12
double-blind (12) 12
drug therapy (12) 12
measuring (12) 12
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (421) 421
French (43) 43
Japanese (38) 38
German (25) 25
Chinese (20) 20
Korean (7) 7
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Progress of theoretical physics. Supplement, ISSN 0375-9687, 11/2004, Volume 155, Issue 155, pp. 367 - 368
Blazars show rapid time variability in X-rays to gamma-rays with large amplitude. The main radiation mechanisms of blazars are thought to be synchrotron... 
VARIABILITY | MODELS | PHYSICS, MULTIDISCIPLINARY
Journal Article
Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1176 - 1181
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma (NEC) of the digestive system. Clinical data from 258 patients with... 
neuroendocrine carcinoma | digestive system | etoposide | irinotecan | Cisplatin | Etoposide | Irinotecan | Digestive system | Neuroendocrine carcinoma | DIAGNOSIS | ETOPOSIDE/CISPLATIN | MANAGEMENT | CELL LUNG-CANCER | PHASE-III TRIAL | CONSENSUS GUIDELINES | IRINOTECAN/CISPLATIN | ONCOLOGY | EXPERIENCE | Leucovorin - administration & dosage | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Cisplatin - administration & dosage | Gastrointestinal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Carcinoma, Neuroendocrine - mortality | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Deoxycytidine - analogs & derivatives | Antimitotic agents | Chemotherapy | Carcinoma | Analysis | Gastrointestinal system | Antineoplastic agents | Cancer | Dehydrogenases | Clinical trials | Multivariate analysis | Intestine | Pancreas | Stomach | Medical research | Research & development--R&D | Histology | Gastrointestinal tract | Survival | Patients | L-Lactate dehydrogenase | Esophagus | Medicine | Hospitals | Medical prognosis | Lactic acid | Neuroendocrine tumors | Pharmaceuticals | Original
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 35, pp. 4438 - 4444
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Cancer Science, ISSN 1347-9032, 07/2014, Volume 105, Issue 7, pp. 812 - 817
This multicenter phase II study first investigated the efficacy and safety of nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) when given every 3 weeks... 
phase II | triweekly | Gastric cancer | nab‐paclitaxel | second‐line chemotherapy | Second-line chemotherapy | nab-paclitaxel | Phase II | Triweekly | PLUS CISPLATIN | CREMOPHOR-FREE | second-line chemotherapy | ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE | SALVAGE CHEMOTHERAPY | SUPPORTIVE CARE | ONCOLOGY | COMPARING IRINOTECAN | COMBINATION CHEMOTHERAPY | 1ST-LINE THERAPY | SOLVENT-BASED PACLITAXEL | Humans | Middle Aged | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Paclitaxel - adverse effects | Male | Stomach Neoplasms - pathology | Treatment Outcome | Stomach Neoplasms - drug therapy | Paclitaxel - therapeutic use | Albumins - therapeutic use | Disease-Free Survival | Antineoplastic Agents, Phytogenic - administration & dosage | Albumins - adverse effects | Leukopenia - chemically induced | Adult | Female | Aged | Antineoplastic Agents, Phytogenic - therapeutic use | Neutropenia - chemically induced | Stomach Neoplasms - mortality | Antineoplastic Agents, Phytogenic - adverse effects | Antimitotic agents | Relapse | Chemotherapy | Clinical trials | Albumin | Product development | Antineoplastic agents | Stomach cancer | Diseases | Cancer | Breast cancer | Metastasis | Neuropathy | Cancer therapies | Disease control | Survival | Blood | Nanoparticles | Lymphopenia | Paclitaxel | Drug dosages | Neutropenia | Pharmaceuticals | Index Medicus | Original
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 183 - 191
This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and... 
Gastroesophageal junction cancer | Medicine & Public Health | Human epidermal growth factor receptor 2 | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | c-MET | Surgical Oncology | Gastric cancer | Epidermal growth factor receptor | 1ST-LINE TREATMENT | CLINICAL-FEATURES | LABEL PHASE-3 TRIAL | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | DOUBLE-BLIND | CARCINOMAS | ESOPHAGOGASTRIC JUNCTION | GASTROENTEROLOGY & HEPATOLOGY | GENE COPY NUMBER | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Receptor, Epidermal Growth Factor - metabolism | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Adenocarcinoma - genetics | Retrospective Studies | Stomach Neoplasms - genetics | Esophagogastric Junction - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Biomarkers, Tumor - genetics | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Immunohistochemistry | Cancer patients | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Cytogenetics | Stomach cancer | Formaldehyde | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1843 - 1850
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line... 
colorectal cancer | RAS mutation | panitumumab | liquid biopsy | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | MULTICENTER | DETERMINANTS | PHASE-III | ACQUIRED-RESISTANCE | FLUOROURACIL | TRIAL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biomarkers, Tumor | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Proto-Oncogene Proteins B-raf | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Retreatment | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Antimitotic agents | Chemotherapy | Endothelial growth factors | Analysis | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Blood proteins | Cancer | Immunoassay | Colorectal carcinoma | Values | Oncology | Serum proteins | Cancer therapies | K-Ras protein | Metastases | Proteins | Oxaliplatin | Epidermal growth factor | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Immunoglobulins | Survival | Patients | Studies | Irinotecan | Biomarkers | Ligands | Original
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2018, Volume 36, Issue 3, pp. 424 - 434
Introduction This phase 1, open-label, multicenter, single-arm, dose-escalation study aimed to evaluate safety, pharmacokinetics (PK), and pharmacodynamics of... 
Pharmacodynamics | Medicine & Public Health | Erdafitinib | Oncology | Phase 1 | Safety | Pharmacology/Toxicology | Pharmacokinetics | DOVITINIB | UROTHELIAL CARCINOMA | CELL LUNG-CANCER | HEPATOCELLULAR-CARCINOMA | CARCINOGENESIS | ONCOLOGY | PHOSPHATE HOMEOSTASIS | PATHWAY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | EXPRESSION | PHASE-2 TRIAL | Protein Kinase Inhibitors - pharmacokinetics | Quinoxalines - adverse effects | Pyrazoles - therapeutic use | Quinoxalines - pharmacokinetics | Area Under Curve | Humans | Middle Aged | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Male | Treatment Outcome | Protein Kinase Inhibitors - adverse effects | Neoplasms - drug therapy | Quinoxalines - pharmacology | Protein Kinase Inhibitors - therapeutic use | Female | Aged | Protein Kinase Inhibitors - pharmacology | Neoplasm Staging | Neoplasms - pathology | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Quinoxalines - therapeutic use | Physiological aspects | Protein tyrosine kinase | Drug therapy | Health aspects | Tumors | Fibroblast growth factor receptors | Fibroblast growth factor | Toxicity | Retina | Retinal pigment epithelium | Fibroblasts | Growth factors | Protein-tyrosine kinase | EKG | Tyrosine | Dosing | Nausea | Pharmacology | Epithelium | Patients | Studies | Stomatitis | Detachment | Inhibitors | Hyperphosphatemia | Solid tumors | Index Medicus
Journal Article